首页> Expert opinion on drug safety> Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system

导出原文传递

翻译打印收藏纠错

第一作者： Huang, Shuohan

作者： Huang, Shuohan ^[1] ; Guo, Zihan ; Wang, Mengmeng ; She, Youjun ; Ye, Xuan ; Zhai, Qing ; Liu, Jiyong ; Du, Qiong

作者单位： Fudan University,Fudan Univ ^[1]

关键词 Adverse event reporting system BRAF and MEK inhibitor combination therapy disproportionality analysis ocular adverse events pharmacovigilance DABRAFENIB PLUS TRAMETINIB MELANOMA VEMURAFENIB SURVIVAL

发布时间 2023-10-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Expert opinion on drug safety

2023年22卷1/6期

175-181页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Expert opinion on drug safety

2023年22卷1/6期

175-181页

检索历史清除

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system

Expert opinion on drug safety

相似文献

同项目论文

Expert opinion on drug safety

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system

Expert opinion on drug safety

相似文献

同项目论文

Expert opinion on drug safety

相关期刊

检索历史清除